Previous 10 | Next 10 |
SOUTH PLAINFIELD, N.J. , Aug. 26, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first comme...
Dyne Therapeutics ( DYN ) has filed a preliminary prospectus for a $100M IPO. More news on: Dyne Therapeutics, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co. Ltd., Healthcare stocks news, IPO News, , Read more ...
Under PRIME status, the European Medicines Agency (EMA) has accepted for review Roche's ( OTCQX:RHHBY ) marketing application seeking approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA). More news on: PTC Therapeutics, Inc., Roche Holding AG, Healthcare s...
SOUTH PLAINFIELD, N.J. , Aug. 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for Evrysdi™ (risdiplam) for the treatment of spinal muscula...
The following companies have filed for mixed shelf offerings: More news on: Calithera Biosciences, Inc., Adaptimmune Therapeutics plc, PTC Therapeutics, Inc., Healthcare stocks news, , Read more ...
Biogen receives priority review for Alzheimer’s drug candidate Biogen ( BIIB ) announced that the FDA has accepted its Biologics License Application for aducanumab. The application has been granted Priority Review and its PDUFA date has been set at March 7, 2021. The agency has ...
I previously wrote about PTC Therapeutics ( PTCT ) on April 30, 2020. Since that time, the company has seen continued progress on multiple fronts, yet the share price has gone down presumably due to a growth rate slowdown caused by the COVID-19 pandemic. I considered PTC to be about fairly val...
Treatment options for nearly everyone born with a lethal muscle-wasting disorder improved on Friday. The U.S. Food and Drug Administration approved Evrysdi from PTC Therapeutics (NASDAQ: PTCT) and Roche (OTC: RHHBY) , making it the third treatment approved for patients with spinal muscula...
PTC Therapeutics ( PTCT +7% ) says the FDA has approved its oral treatment for spinal muscular atrophy Evrysdi (risdiplam), which will available for U.S. patients within two weeks. More news on: PTC Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SOUTH PLAINFIELD, N.J. , Aug. 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adul...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....